Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Current Leases (2019 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Current Leases for 7 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 18.64% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Dec 2025, up 18.64%, and an annual FY2025 reading of $4.2 million, up 18.64% over the prior year.
  • Current Leases was $4.2 million for Q4 2025 at Arcturus Therapeutics Holdings, up from $4.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $4.3 million in Q4 2023 and bottomed at $1.5 million in Q4 2021.
  • Average Current Leases over 5 years is $3.5 million, with a median of $3.9 million recorded in 2022.
  • The sharpest move saw Current Leases soared 152.7% in 2022, then decreased 18.21% in 2024.
  • Year by year, Current Leases stood at $1.5 million in 2021, then skyrocketed by 152.7% to $3.9 million in 2022, then rose by 10.94% to $4.3 million in 2023, then decreased by 17.57% to $3.6 million in 2024, then rose by 18.64% to $4.2 million in 2025.
  • Business Quant data shows Current Leases for ARCT at $4.2 million in Q4 2025, $4.0 million in Q2 2025, and $3.6 million in Q4 2024.